Morning Market Losers - Exact Sciences (NASDAQ:EXAS), Haemonetics (NYSE:HAE)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

EXACT Sciences Corporation (NASDAQ: EXAS) shares dipped 38.48 percent to $11.40. Benchmark downgraded Exact Sciences to Hold and lowered the price target from $34.00 to $11.00.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Radware Ltd. (NASDAQ: RDWR) shares slipped 25.23 percent to $12.95 after the company issued a weak Q3 forecast. Illumina, Inc. (NASDAQ: ILMN) shares dropped 19.18 percent to $131.88 after the company issued a weak revenue forecast. Container Store Group Inc

FREE REPORT: How To Learn Options Trading Fast

In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.

(NYSE: TCS) shares fell 11.18 percent to $13.83 after the company reported weaker-than-expected results for its fiscal second quarter. O2Micro International Limited (ADR)

(NASDAQ: OIIM) dropped 6.64 percent to $2.11 after the company lowered its Q3 sales outlook.Haemonetics Corporation (NYSE: HAE) shares slipped 6.38 percent to $31.25 after the company lowered its forecast for the year.Sarepta Therapeutics Inc (NASDAQ: SRPT) dropped 5.19 percent to $39.62 after the company priced 3.25 million shares of common stock at $39 per share. Tesla Motors Inc (NASDAQ: TSLA) declined 2.30 percent to $240.50. Analysts at Morgan Stanley maintained Overweight rating for Tesla Motors and lowered the target price from $465 to $450.